A Look at Teva's Generic Drugs Research Pipeline
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | FiercePharma
Teva Pharmaceutical: Generic Market Access to Global Healthcare Industry | IntechOpen
SymBio Pharmaceuticals : Pipeline : Treakisym® SyB L-0501
Teva Stock Offers Maximum Optimism For Investors (NYSE:TEVA) | Seeking Alpha
Teva-Takeda joint venture divests certain assets in Japan to Nichi-Iko - Pharmaceutical Technology
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Pharm Exec's 2020 Pipeline Report
Teva's drug pipeline could contain blockbusters - Globes
Producing Quality Products | Teva Pharmaceuticals
Celltrion FDA warning causes headache for Teva's biologics ambition
EX-99.1
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
EX-99.1
Israel's Teva on FDA blacklist of drugmakers creating barriers to competition | The Times of Israel
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
Teva Announces FDA Approval of First and Only Digital Inhaler with Built-In Sensors – ProAir® Digihaler™ | SnackSafely.com
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
Fresh from the biotech pipeline—2012 | Nature Biotechnology
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches :: Scrip
FDA approves first generic version of epilepsy drug Sabril from Teva
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace
EX-99.1
Sosei see Teva pipeline cull as an opportunity -
Refreshing the biologic pipeline 2020 | Nature Biotechnology
